Published in J Mol Diagn on March 19, 2010
Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci (2014) 1.05
Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine. PLoS One (2014) 0.91
Biomarkers in prostate cancer epidemiology. Cancers (Basel) (2011) 0.84
PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. Clin Epigenetics (2016) 0.77
DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract. PLoS One (2016) 0.76
PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma. Clin Epigenetics (2017) 0.75
Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. Int J Mol Sci (2017) 0.75
[Molecular biomarkers and prognostic factors for prostate cancer]. Urologe A (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
The epigenomics of cancer. Cell (2007) 30.91
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
DNA methylation and human disease. Nat Rev Genet (2005) 12.00
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (1998) 8.33
Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol (2002) 7.17
DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol (2005) 5.02
Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet (1996) 4.21
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
Identification of a Wnt/Dvl/beta-Catenin --> Pitx2 pathway mediating cell-type-specific proliferation during development. Cell (2002) 3.37
Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis. Nature (1999) 2.64
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene (2006) 2.05
Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology (2008) 1.66
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res (2007) 1.30
Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.26
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res (2000) 1.26
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol (2005) 1.21
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol (2008) 1.19
Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol (2008) 1.18
DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res (2009) 1.12
Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. J Histochem Cytochem (2009) 1.12
Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res (2005) 1.08
Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol (2007) 1.08
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat (2007) 1.08
Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol (2008) 0.98
Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol (2004) 0.96
Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer. Cancer Sci (2007) 0.91
IGF-II promoter methylation and ovarian cancer prognosis. J Cancer Res Clin Oncol (2007) 0.87
A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. Cancer Lett (2004) 0.85
DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet (2006) 18.08
Parallel patterns of evolution in the genomes and transcriptomes of humans and chimpanzees. Science (2005) 5.68
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer (2010) 4.53
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol (2010) 4.11
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
Regional patterns of gene expression in human and chimpanzee brains. Genome Res (2004) 3.84
A neutral model of transcriptome evolution. PLoS Biol (2004) 3.44
Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A (2004) 3.40
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol (2011) 2.89
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem (2007) 2.65
Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol (2009) 2.60
Pathways that make voices: white matter changes in auditory hallucinations. Arch Gen Psychiatry (2004) 2.57
Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem (2009) 2.57
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development (2002) 2.42
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys (2007) 2.42
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology (2003) 2.40
Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res (2002) 2.34
FUNC: a package for detecting significant associations between gene sets and ontological annotations. BMC Bioinformatics (2007) 2.32
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol (2003) 2.30
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut (2013) 2.17
Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med (Berl) (2005) 2.16
MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med (2009) 2.12
Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC). BJU Int (2013) 2.10
Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res (2008) 2.06
Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol (2003) 2.04
Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol (2007) 2.02
Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eur Urol (2008) 2.02
Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. Eur Urol (2013) 2.00
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol (2007) 1.93
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol (2007) 1.89
Reduced Y-chromosome, but not mitochondrial DNA, diversity in human populations from West New Guinea. Am J Hum Genet (2002) 1.86
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer (2011) 1.83
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol (2010) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol (2008) 1.78
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest (2006) 1.78
The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res (2010) 1.75
Recent origin and cultural reversion of a hunter-gatherer group. PLoS Biol (2005) 1.75
Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol (2011) 1.72
FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol (2007) 1.72
Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte. Eur Urol (2006) 1.71
Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat (2011) 1.71
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol (2007) 1.68
Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One (2012) 1.67
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res (2006) 1.66
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
ERG rearrangement in small cell prostatic and lung cancer. Histopathology (2010) 1.64
Genetic background controls tumor development in PTEN-deficient mice. Cancer Res (2006) 1.63
Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer (2008) 1.63
The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol (2009) 1.62
Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol (2005) 1.60
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res (2004) 1.58
Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol (2002) 1.57
Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol (2002) 1.56
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer (2003) 1.55
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol (2010) 1.55
HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol (2003) 1.55
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol (2006) 1.54
Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation (2012) 1.52
Performance of a Medipix3RX spectroscopic pixel detector with a high resistivity gallium arsenide sensor. IEEE Trans Med Imaging (2014) 1.51
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res (2005) 1.50
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat (2007) 1.49
Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours. Neuropathol Appl Neurobiol (2015) 1.49
miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis. Inflamm Bowel Dis (2015) 1.47
MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer (2011) 1.47
On a dark-field signal generated by micrometer-sized calcifications in phase-contrast mammography. Phys Med Biol (2013) 1.47
Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry. Nucleic Acids Res (2003) 1.46
Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis. Gastroenterology (2006) 1.46
Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma. Eur Urol (2012) 1.46
Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol (2011) 1.44